BioXcel Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2023.

If you purchased BioXcel Therapeutics securities during the Class Period and would like to join the action, please click “Join This Class Action.”

Class Period:December 15, 2021 through June 28, 2023
If you purchased BioXcel Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations or prospects. Specifically, defendants failed to disclose to investors:

  • BioXcel Therapeutics lacked adequate internal controls over protocol adherence and data integrity;
  • as a result, BioXcel Therapeutics’s principal investigator failed to adhere to the informed consent form approved by the Institutional Review Board (“IRB”);
  • BioXcel Therapeutics’s principal investigator failed to maintain adequate case histories for certain patients whose records were reviewed by the U.S. Food and Drug Administration (“FDA”);
  • BioXcel Therapeutics’s principal investigator fabricated email correspondence with a pharmacovigilance safety vendor that was then provided to the FDA;
  • the foregoing would negatively impact BioXcel Therapeutics’s ability to obtain regulatory approval of BXCL501 (which is purportedly a proprietary, orally dissolving, film formulation of dexmedetomidine, or “Dex”) for the treatment of agitation associated with dementia in patients with probable Alzheimer’s disease; and
  • as a result of the foregoing, defendants’ positive statements about BioXcel Therapeutics’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Follow us on:
Company Name: BioXcel Therapeutics, Inc.
Stock Symbol: BTAI
Class Period: December 15, 2021 through June 28, 2023
Court: United States District Court for the District of Connecticut

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top